3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
13
Phase 1
9
Phase 1/2
6
Phase 3
2
Status
Recruiting
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
HER2+ Metastatic Breast Cancer (MBC)
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
297
Cisplatin
297
Paclitaxel
258
Radiotherapy
253
Fluorouracil
234
Carboplatin
234
Docetaxel
231
Doxorubicin
212
Dexamethasone
164
Gemcitabine
155
Vincristine
143
Etoposide
133
Leucovorin
132
Capecitabine
129
Bevacizumab
129
Prednisone
124
Rituximab
118
Methotrexate
117
Cytarabine
108
Filgrastim
99
Trastuzumab
98
Oxaliplatin
96
pembrolizumab
81
Pemetrexed
73
Epirubicin
70
Tamoxifen
69
Drug Therapy
69
Irinotecan
65
Granulocyte Colony-Stimulating Factor
60
Nivolumab
57
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Completed
×
neratinib
×
Clear all
NCT00878709
2021-06-11
ExteNET
Puma Biotechnology, Inc.
Phase 3
Completed
2,840 enrolled
25 charts
1 FDA
NCT01808573
2021-06-11
NALA
Puma Biotechnology, Inc.
Phase 3
Completed
621 enrolled
21 charts
1 FDA